Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines

被引:8
|
作者
Kim, Ji Yeun [1 ]
Bae, Seongman [1 ]
Park, Soonju [2 ]
Kwon, Ji-Soo [1 ]
Lim, So Yun [1 ]
Park, Ji Young [1 ]
Cha, Hye Hee [1 ]
Seo, Mi Hyun [1 ]
Lee, Hyun Jung
Lee, Nakyung [2 ]
Heo, Jinyeong [2 ]
Shum, David [2 ]
Jee, Youngmee [2 ]
Kim, Sung-Han [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Inst Pasteur Korea, 16 Daewangpangyo Ro 712 Beon Gil, Seongnam 13488, South Korea
基金
新加坡国家研究基金会;
关键词
Immunogenicity; Antibody response; T cell response; ChAdOx1; nCoV-19; vaccine; BNT162b2;
D O I
10.4110/in.2021.21.e29
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There are limited data directly comparing humoral and T cell responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines. We compared Ab and T cell responses after first doses of ChAdOx1 nCoV-19 vs. BNT162b2 vaccines. We enrolled healthcare workers who received ChAdOx1 nCoV-19 or BNT162b2 vaccine in Seoul, Korea. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S1 protein-specific IgG Abs (S1-IgG), neutralizing Abs (NT Abs), and SARS-CoV-2-specific T cell response were evaluated before vaccination and at 1-wk intervals for 3 wks after vaccination. A total of 76 persons, comprising 40 injected with the ChAdOx1 vaccine and 36 injected with the BNT162b2 vaccine, participated in this study. At 3 wks after vaccination, the mean levels (+/- SD) of S1-IgG and NT Abs in the BNT162b2 participants were significantly higher than in the ChAdOx1 participants (S1-IgG, 14.03 +/- 7.20 vs. 6.28 +/- 8.87, p<0.0001; NT Ab, 183.1 +/- 155.6 vs. 116.6 +/- 116.2, p=0.035), respectively. However, the mean values of the T cell responses in the 2 groups were comparable after 2 wks. The humoral immune response after the 1st dose of BNT162b2 developed faster and was stronger than after the 1st dose of ChAdOx1. However, the T cell responses to BNT162b2 and ChAdOx1 were similar.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
    Karan Pattni
    Daniel Hungerford
    Sarah Adams
    Iain Buchan
    Christopher P. Cheyne
    Marta García-Fiñana
    Ian Hall
    David M. Hughes
    Christopher E. Overton
    Xingna Zhang
    Kieran J. Sharkey
    BMC Infectious Diseases, 22
  • [32] Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
    Pattni, Karan
    Hungerford, Daniel
    Adams, Sarah
    Buchan, Iain
    Cheyne, Christopher P.
    Garcia-Finana, Marta
    Hall, Ian
    Hughes, David M.
    Overton, Christopher E.
    Zhang, Xingna
    Sharkey, Kieran J.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [33] Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data
    Paris, Christophe
    Perrin, Sophie
    Hamonic, Stephanie
    Bourget, Baptiste
    Roue, Clemence
    Brassard, Olivier
    Tadie, Emilie
    Gicquel, Vincent
    Benezit, Francois
    Thibault, Vincent
    Garlantezec, Ronan
    Tattevin, Pierre
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (11) : 1699.e5 - 1699.e8
  • [34] Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
    Havervall, Sebastian
    Marking, Ulrika
    Greilert-Norin, Nina
    Ng, Henry
    Gordon, Max
    Salomonsson, Ann-Christin
    Hellstrom, Cecilia
    Pin, Elisa
    Blom, Kim
    Mangsbo, Sara
    Phillipson, Mia
    Klingstrom, Jonas
    Hober, Sophia
    Nilsson, Peter
    Aberg, Mikael
    Thalin, Charlotte
    EBIOMEDICINE, 2021, 70
  • [35] Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers
    Oktay Gultekin, Efdal
    Gultekin, Onur
    INDIAN JOURNAL OF MICROBIOLOGY, 2023, 63 (03) : 361 - 368
  • [36] Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
    Vivaldi, Giulia
    Jolliffe, David A.
    Holt, Hayley
    Tydeman, Florence
    Talaei, Mohammad
    Davies, Gwyneth A.
    Lyons, Ronan A.
    Griffiths, Christopher J.
    Kee, Frank
    Sheikh, Aziz
    Shaheen, Seif O.
    Martineau, Adrian R.
    LANCET REGIONAL HEALTH-EUROPE, 2022, 22
  • [37] Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 nCoV-19 Vaccine
    Suwanwattana, Pawita
    Han, May
    Nopsopon, Tanawin
    Phutrakool, Phanupong
    Samuthpongtorn, Chatpol
    Pongpirul, Wannarat
    Prasithsirikul, Wisit
    Pongpirul, Krit
    MICROBIOLOGY RESEARCH, 2023, 14 (02) : 810 - 818
  • [38] Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
    Niyomnaitham, Suvimol
    Quan Toh, Zheng
    Wongprompitak, Patimaporn
    Jansarikit, Laddawan
    Srisutthisamphan, Kanjana
    Sapsutthipas, Sompong
    Jantraphakorn, Yuparat
    Mingngamsup, Natthakarn
    Licciardi, Paul, V
    Chokephaibulkit, Kulkanya
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [39] Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
    Hermosilla, Eduardo
    Coma, Ermengol
    Xie, Junqing
    Feng, Shuo
    Cabezas, Carmen
    Mendez-Boo, Leonardo
    Fina, Francesc
    Ballo, Elisabet
    Martinez, Montserrat
    Medina-Peralta, Manuel
    Argimon, Josep Maria
    Prieto-Alhambra, Daniel
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [40] COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2middot57 million people in Scotland (EAVE II): a prospective cohort study
    Agrawal, Utkarsh
    Katikireddi, Srinivasa Vittal
    McCowan, Colin
    Mulholland, Rachel H.
    Azcoaga-Lorenzo, Amaya
    Amele, Sarah
    Fagbamigbe, Adeniyi Francis
    Vasileiou, Eleftheria
    Grange, Zoe
    Shi, Ting
    Kerr, Steven
    Moore, Emily
    Murray, Josephine L. K.
    Shah, Syed Ahmar
    Ritchie, Lewis
    O'Reilly, Dermot
    Stock, Sarah J.
    Beggs, Jillian
    Chuter, Antony
    Torabi, Fatemah
    Akbari, Ashley
    Bedston, Stuart
    McMenamin, Jim
    Wood, Rachael
    Tang, Ruby S. M.
    de Lusignan, Simon
    Hobbs, F. D. Richard
    Woolhouse, Mark
    Simpson, Colin R.
    Robertson, Chris
    Sheikh, Aziz
    LANCET RESPIRATORY MEDICINE, 2020, 9 (12) : 1439 - 1449